BCHE and neutropenia: Grade 1–2 adverse events occurred in 70.6% of patients and included dermatologic manifestations (mild transient stomatitis, worsening of infantile acne), subclinical laboratory changes (increase of cholesterol and triglycerides, changes in phosphate levels, increase of cholinesterase and lactate dehydrogenase, transient anemia and neutropenia) as well as uncomplicated infections.